Müschen M - Search Results

1

Involvement of soluble CD95 in Churg-Strauss syndrome.

Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Müschen M, et al. Am J Pathol. 1999 Sep;155(3):915-25. doi: 10.1016/S0002-9440(10)65191-7. Am J Pathol. 1999. PMID: 10487849 Free PMC article.

2

Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in human embryonal carcinoma cells by interferon gamma and all-trans retinoic acid.

Müschen M, Warskulat U, Schmidt B, Schulz WA, Häussinger D. Müschen M, et al. Biol Chem. 1998 Aug-Sep;379(8-9):1083-91. doi: 10.1515/bchm.1998.379.8-9.1083. Biol Chem. 1998. PMID: 9792441

3

Regulation of CD95 (Apo-1/Fas) ligand and receptor expression in squamous-cell carcinoma by interferon-gamma and cisplatin.

Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann MW, Häussinger D. Moers C, et al. Among authors: muschen m. Int J Cancer. 1999 Feb 9;80(4):564-72. doi: 10.1002/(sici)1097-0215(19990209)80:4<564::aid-ijc14>3.0.co;2-x. Int J Cancer. 1999. PMID: 9935158 Free article.

4

Involvement of CD95 (Apo-1/Fas) ligand expressed by rat Kupffer cells in hepatic immunoregulation.

Müschen M, Warskulat U, Peters-Regehr T, Bode JG, Kubitz R, Häussinger D. Müschen M, et al. Gastroenterology. 1999 Mar;116(3):666-77. doi: 10.1016/s0016-5085(99)70189-7. Gastroenterology. 1999. PMID: 10029626

5

CD95 ligand expression in dedifferentiated breast cancer.

Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann MW, Häussinger D. Müschen M, et al. J Pathol. 1999 Nov;189(3):378-86. doi: 10.1002/(SICI)1096-9896(199911)189:3<378::AID-PATH439>3.0.CO;2-D. J Pathol. 1999. PMID: 10547600

6

CD95 ligand expression as a mechanism of immune escape in breast cancer.

Müschen M, Moers C, Warskulat U, Even J, Niederacher D, Beckmann MW. Müschen M, et al. Immunology. 2000 Jan;99(1):69-77. doi: 10.1046/j.1365-2567.2000.00921.x. Immunology. 2000. PMID: 10651943 Free PMC article.

7

Defining CD95 as a tumor suppressor gene.

Müschen M, Warskulat U, Beckmann MW. Müschen M, et al. J Mol Med (Berl). 2000;78(6):312-25. doi: 10.1007/s001090000112. J Mol Med (Berl). 2000. PMID: 11001528 Review.

8

Regulation of CD95 (APO-1/Fas) receptor and ligand expression by lipopolysaccharide and dexamethasone in parenchymal and nonparenchymal rat liver cells.

Müschen M, Warskulat U, Douillard P, Gilbert E, Häussinger D. Müschen M, et al. Hepatology. 1998 Jan;27(1):200-8. doi: 10.1002/hep.510270131. Hepatology. 1998. PMID: 9425938

9

Deranged CD95 system in a case of Churg-Strauss vasculitis.

Müschen M, Warskulat U, Häussinger D, Moers C, Simon D, Even J. Müschen M, et al. Gastroenterology. 1998 Jun;114(6):1351-2. doi: 10.1016/s0016-5085(98)70458-5. Gastroenterology. 1998. PMID: 9618660 No abstract available.

10

Resistance to CD95-mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene.

Müschen M, Re D, Betz B, Moers C, Wolf J, Niederacher D, Diehl V, Beckmann MW. Müschen M, et al. Int J Cancer. 2001 Apr 15;92(2):309-10. doi: 10.1002/1097-0215(200102)9999:9999<::aid-ijc1188>3.0.co;2-5. Int J Cancer. 2001. PMID: 11291062 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page